Overview
IDEAYA Q3 net income of $119.2 mln, beating analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting strong financial performance
Collaboration revenue for Q3 at $207.8 mln, driven by Servier agreement
Outlook
IDEAYA to report PFS data for darovasertib trial by end of 2025 to Q1 2026
IDEAYA plans Phase 3 trial for darovasertib as adjuvant therapy in H1 2026
IDEAYA expects clinical update for IDE397 and Trodelvy combo in H1 2026
Result Drivers
SERVIER AGREEMENT - $210 mln upfront payment from exclusive license agreement with Servier for darovasertib rights outside the US
CASH POSITION - IDEAYA's cash and marketable securities increased to $1.14 bln, expected to fund operations into 2030
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Collaboration Revenue | $207.83 mln | ||
Q3 EPS | Beat | $1.35 | -$0.54 (16 Analysts) |
Q3 Net Income | Beat | $119.24 mln | -$45.13 mln (14 Analysts) |
Q3 Profit From Operations | Beat | $108.45 mln | -$56.61 mln (14 Analysts) |
Q3 Operating Expenses | $99.38 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $45.00, about 30.3% above its November 3 closing price of $31.36
Press Release: ID:nPn18TcKza
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)